✦ LIBER ✦

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

✍ Scribed by Russell J. Schilder; Harsh B. Pathak; Anna E. Lokshin; Robert W. Holloway; Ronald D. Alvarez; Carol Aghajanian; Hua Min; Karthik Devarajan; Eric Ross; Charles W. Drescher; Andrew K. Godwin

Book ID: 113961913
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 425 KB
Volume: 113
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2008.12.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II clinical trial of bevacizumab w

Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

✍ Tillmanns, Todd D.; Lowe, M. Patrick; Walker, Mark S.; Stepanski, Edward J.; Sch 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 322 KB

Phase I trial of autologous hematopoieti

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma

✍ Litzow, M R; Peethambaram, P P; Safgren, S L; Keeney, G L; Ansell, S M; Dispenzi 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 189 KB

Randomised phase II study of docetaxel p

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904

✍ Coleman, Robert L.; Moon, James; Sood, Anil K.; Hu, Wei; Delmore, James E.; Bone 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 887 KB

Evaluation of Monoclonal Humanized Anti-

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

✍ Bookman, M. A. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 108 KB

A Gynecologic Oncology Group phase II tr

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

✍ Lydia Usha; Michael W. Sill; Kathleen M. Darcy; Doris M. Benbrook; Jean A. Hurte 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 397 KB

A phase II trial of intraperitoneal EGEN

A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: A GOG study

✍ Alvarez, R.D.; Sill, M.; Davidson, S.A.; Muller, C.; Bender, D.P.; DeBernardo, R 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 94 KB